GOG-263: Randomized phase III clinical trial of adjuvant radiation versus chemoradiation in intermediate risk, stage I/IIA cervical cancer treated with initial radical hysterectomy and pelvic lymphadenectomy,
Role: Investigator,
Southwest Oncology Group,
(09/2024 - 09/2025)
Status: Approved
Southwest Oncology Group (SWOG) S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in rare tumors,
Role: Investigator,
Southwest Oncology Group,
(12/2024 - 12/2025)
Status: Approved
SWOG / NRG-GY009: A Randomized, Phase II/III Study of Pegylated Lipsomal Doxorubicin and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian Cancer,
Role: Investigator,
Southwest Oncology Group,
(12/2019)
Status: Completed
NRG-GY018, A Phase Ill Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475) in addition to Paclitaxel and Carboplatin for Measurable Stage Ill or IVA, Stage IVB or Recurrent Endometrial Cancer (NCT # 03914612) (09/24/2019),
Role: Investigator,
Southwest Oncology Group,
(02/2024)
Status: Completed
Internal
The impact of air pollution on gynecologic malignancies,
Role: Investigator,
LLU Dept. of Gynecology & Obstetrics,
(05/2024)
Status: Approved
Percutaneous Nephrostomy Complications in Gynecologic Cancers,
Role: Investigator,
LLU Dept. of Gynecology & Obstetrics,
(05/2024)
Status: Approved
Investigator initiated: Conventional prophylactic regimen of oral dexamethasone versus short-course intravenous dexamethasone in preventing paclitaxel-related hypersensitivity reactions in breast and gynecologic-oncology patients: A prospective, randomized, open-label study,
Role: Investigator,
LLU Dept. of Gynecology & Obstetrics,
(02/2024 - 01/2025)
Status: Completed
Investigator initiated: Retrospective analysis to determine the incidence of Occult Cervical cancer in patients with Adenocarcinoma in situ at LLU,
Role: Investigator,
LLU Dept. of Gynecology & Obstetrics,
(02/2019)
Status: Approved
Compassionate use of everolimus: Individual patient program (IPP) for treatment of recurrent progressive clear cell endocervical cancer with everolimus,
Role: Investigator,
LLU Dept. of Gynecology & Obstetrics,
Status: Completed
LLU Cancer Center biospecimen laboratory - specimens collection protocol,
Role: Investigator,
LLU Cancer Institute,
(09/2024 - 09/2025)
Status: Approved
Evaluating DNA recovered from the fluids collected during a routine Papanicolaou (Pap) test to detect ovarian and endometrial cancer using genetic analysis,
Role: Investigator,
LLU Dept. of Pathology & Human Anatomy,
(12/2024 - 12/2025)
Status: Approved